drugset
drugset / Trial / NCT00894439

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

NCT00894439 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate how BLI-489 and piperacillin interact when given together to healthy subjects.

Timeline

Start
2009-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BLI-489 Small molecule — —
Subject Piperacillin Small molecule — —

Indications

No indication recorded.